Drug Profile


Alternative Names: WCK-5107

Latest Information Update: 30 Dec 2016

Price : $50

At a glance

  • Originator Wockhardt
  • Class Antibacterials; Azabicyclo compounds; Piperidines; Small molecules; Sulfoxides
  • Mechanism of Action Penicillin-binding protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Bacterial infections

Most Recent Events

  • 26 Oct 2016 Adverse events and pharmacokinetics data from a phase I trial in Healthy subjects presented at the IDWeek 2016
  • 16 Aug 2016 Wockhardt completes a phase I pharmacokinetic trial in Healthy volunteers in USA (NCT02674347)
  • 01 Feb 2016 Wockhardt initiates a phase I pharmacokinetic trial in Healthy volunteers in USA (NCT02674347)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top